CAR-T cell therapy is a groundbreaking form of immunotherapy, with seven US FDA-approved therapies for hematological malignancies and ongoing investigations for solid tumors. This autologous therapy includes harvesting patient’s T cells, engineering them to express CAR constructs, and transfusing them back into the patient to target and destroy cancer cells. In this study, we evaluated five LNP formulations to express a reporter gene (eGFP mRNA) in microbubble-CD3/CD28-activated T cells and stimulated with IL-2 and IL-7.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Nyayapathy, S., Gronevelt, J.P., Holcomb, E., et al. ​Lipid nanoparticle-mediated in vitro transfection of microbubble-activated T cells. Poster presented at: American Association for Cancer Research Annual Meeting 2025; April 25-30, 2025; Chicago, IL.